Clinical Trial

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Currently, there are no standard treatment and relevant exploration for NSCLC patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with tislelizumab in the treatment of NSCLC with NED, in order to provide a new treatment option for NSCLC patients with NED.
Trial Details
NCT Number NCT06414915
Lead Sponsor National Cancer Center, China
Conditions NSCLC
Enrollment 29 participants
Start Date 2024-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-16